Drug intelligence / Profile preview

NKF202

Development stage: Preclinical
Lead developer: PUMC Pharmaceutical

Overview

NKF202 is a preclinical drug candidate being developed by PUMC Pharmaceutical (Beijing PUMC Pharmaceutical Co., Ltd.) for the treatment of nephrological conditions. It is currently listed in the company's research and development pipeline as a project in the preclinical phase. Due to the early stage of development, specific information regarding its chemical modality (e.g., small molecule vs. biologic), molecular target, and precise mechanism of action has not been publicly disclosed. The 'NKF' designation is used by PUMC Pharmaceutical for several of its nephrology-focused research programs, including NKF101 and NKF201.

Beyond the preview

Go deeper on NKF202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKF202.

Explore the full profile